Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | PHASE1 | COMPLETED | 133 | — | — | Jun 15, 2018 | Jun 1, 2023 | Jan 23, 2024 | 25 | United States, South Korea +2 |
| Arm | Type | Description |
|---|---|---|
| CX-2029 Escalation | EXPERIMENTAL | Dose Escalation and Determination |
| CX-2029 Biomarker | EXPERIMENTAL | Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types |
| CX-2029 Expansion | EXPERIMENTAL | Evaluate antitumor activity of CX-2029 |
| Name | Type | Description |
|---|---|---|
| CX-2029 | DRUG | CX-2029 Monotherapy |
Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable tumors 2. Patients demonstrating disease progression after treatment with approved therapies that are known to confer life-prolonging benefit, or who are intolerant to or have d...